Evidence map›Paper›PMID 28980045›Full record

ReviewDer Urologe. Ausg. A2017

[The role of PSMA PET-CT in patients with metastatic prostate cancer].

J von Hardenberg, K-A Büsing, P Nuhn, M Ritter

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Urologe. Ausg. A, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

J von HardenbergKlinik für Urologie, Universitätsmedizin Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Deutschland. Jost.vonhardenberg@medma.uni-heidelberg.de.
K-A BüsingInstitut für Klinische Radiologie und Nuklearmedizin der Universitätsmedizin Mannheim, Universität Heidelberg, Mannheim, Deutschland.
P NuhnKlinik für Urologie, Universitätsmedizin Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Deutschland.
M RitterKlinik für Urologie, Universitätsmedizin Mannheim, Universität Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Deutschland.
Heidelberg University · DEUniversity Hospital Heidelberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate-specific membrane antigen (PSMA) positron emission tomography-computed tomography (PET-CT) imaging for the localization of prostate cancer is increasingly available in Germany. The advances and limitations in different disease stages are reviewed. As the clinical relevance of oligometastatic disease in primary cancer detected by PSMA PET-CT imaging is not yet completely understood, it should only be used in clinical trials. In recurrent prostate cancer after therapy with curative intent, PSMA PET-CT shows encouraging potential for the planning of salvage therapy. In metastatic castration-resistant prostate cancer evidence for its use is not available.

Indexed as

Antigens, SurfaceDisease ProgressionGlutamate Carboxypeptidase IIHumansMaleNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPositron Emission Tomography Computed TomographyPrognosisProstatic NeoplasmsProstatic Neoplasms, Castration-ResistantSalvage TherapyAntigens, SurfaceFOLH1 protein, humanGlutamate Carboxypeptidase IICastration-resistant prostate cancer (CRPC)OligometastasesPrimary diagnosticProstatectomy, radicalRecurrence

Identifiers

PMID28980045
OpenAlexW2763829029

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.